Showing 89 of 89 results

PATH
Il s’agit d’un outil simple dans Excel qui permet d’évaluer et de comparer les coûts des programmes de vaccination VPC (vaccin pneumococcique conjugué) sur un an et sur une période totale...
Chair Hani Kim
Narendra Arora (INCLEN), David Durrheim (University of Newcastle), Pradeep Haldar (MOHFW, India), Keith Klugman (BMGF), Kate O’Brien (International Vaccine Access Center), Collins Tabu (Ministry of...
World Health Organization (WHO)
The WHO initiative, Market Information for Access to Vaccines (MI4A) produces vaccine-specific market studies, analyzing global demand and supply prospects for individual vaccines. The studies...
PATH
PATH's Pneumococcal Conjugate Vaccine Cost Calculator is a simple, Excel-based tool for assessing and comparing costs of pneumococcal conjugate vaccine (PCV) programs annually and for a period of 10...
World Health Organization (WHO)
Summary guidance for national authorities and immunization programme managers for the switch from GlaxoSmithKline Biologicals SA Synflorix® (PCV 10) to Pfizer Prevenar13® vaccine (PCV 13)
Gavi, the Vaccine Alliance
Based on current timelines, PCV13 4-dose vials have become available to Gavi countries in 2017 and PCV10 4-dose vials are forecasted to become available in 2018. The availability of PCV10 4-dose...
World Health Organization (WHO)
This table displays the characteristics of different presentations of Pneumococcal Conjugate Vaccines
KinleyDorji et al.
Background: Due to competing health priorities and limited resources, many low-income countries, even those with a high disease burden, are not able to introduce pneumococcal conjugate vaccines....
International Vaccine Access Center (IVAC)
Each year, IVAC prepares the Pneumonia and Diarrhea Progress Report and publishes it for World Pneumonia Day on November 12. The report evaluates the annual progress made in prevention and control of...
Philippe De Wals et al.
Background: In Quebec, 7-valent (PCV7), 10-valent (PCV10) and 13-valent (PCV13) pneumococcal conjugate vaccines were successively used for the immunization of children according to a 2+1 doses...
International Vaccine Access Center (IVAC)
Each year, IVAC prepares the Pneumonia and Diarrhea Progress Report and publishes it for World Pneumonia Day on November 12. The report evaluates the annual progress made in prevention and control of...
Grace M. Lee et al.
BACKGROUND: Rates of invasive pneumococcal disease have declined since widespread introduction of pneumococcal conjugate vaccines (PCVs) in the United States. We evaluated the impact of immunization...
Rhiannon R.Penkert et al.
Streptococcus pneumoniae (pneumococcus) is responsible for serious pediatric respiratory infections, and kills close to one million children under the age of five each year. Unfortunately, the...
Folake Olayinka et al.
The number of vaccines available to low-income countries has increased dramatically over the last decade. Overall infant immunization coverage in the WHO African region has stagnated in the past few...
Background: Streptococcus pneumoniae is a leading cause of vaccine-preventable disease in children under 5 years. Immunocompromised children and those with underlying diseases are at increased risk...
William P. Hausdorffa, Steve Black
Pneumococcal conjugate vaccines have proven highly effective in decreasing invasive disease and pneumonia in young children. However, there is considerable geographic variability in the impact of...
González-Escartín E et al.
OBJECTIVE: To analyze the characteristics of pneumococcal meningitis in children ≤ 14 years old following the market introduction of pneumococcal conjugate vaccines in our community. METHODS:...
International Vaccine Access Center (IVAC)
To address the epidemiologic and diagnostic complexity of pneumococcal disease in particular, and to support our partners in their technical evaluations of pneumococcal disease and vaccines, we are...
International Vaccine Access Center (IVAC)
IVAC is releasing a set of tools capturing and synthesizing the latest and best available data around pneumococcal diseases and vaccines with technical decision-makers in mind. We have developed a...
International Vaccine Access Center (IVAC)
The global analysis, entitled Gap Analyses of PCV Impact Evaluations in Settings of Routine Use, is the output of an IVAC-maintained database of completed and ongoing vaccine impact studies for these...
Palmu AA
BACKGROUND: The ten-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Finnish National Vaccination Program (NVP) in September 2010 using a 2+1 schedule (3, 5, 12 months). We...
Jayasinghe S et al.
BACKGROUND: Australia introduced universal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 2011, uniquely among high-income countries giving doses at 2,...
James Smith
On Oct 10, 2015, Médecins Sans Frontières (MSF) rejected Pfizer\'s proposed donation of 1 million doses of its branded pneumococcal conjugate vaccine (PCV).1 The news caused a stir in the global...
Sara Boccalini, Angela Bechini, Alessio Signori, Stefano Carozzo, Lucia Arata, Daniela Amicizia , Giancarlo Icardi, Paolo Bonanni, Roberto Gasparini, Alexander Domnich, Donatella Panatto
BACKGROUND The recently launched Pneumo Rischio eHealth project, which consists of an app, a website, and social networking activity, is aimed at increasing public awareness of invasive pneumococcal...
Cynthia Schuck-Paim et al.
Because the real-world impact of new vaccines cannot be known before they are implemented in national programs, post-implementation studies at the population level are critical. Studies based on...
M. Tashani et al.
Sequential or co-administration of vaccines has potential to alter the immune response to any of the antigens. Existing literature suggests that prior immunisation of tetanus/diphtheria-containing...
Dilip Mathai et al.
Respiratory tract infections are prevalent among Hajj pilgrims with pneumonia being a leading cause of hospitalization. Streptococcus pneumoniae is a common pathogen isolated from patients with...
Rongcheng Li et al.
Abstract Background In a previous study, Chinese infants were vaccinated with 7-valent pneumococcal conjugate vaccine (PCV7) ⩾7 days before routine diphtheria, tetanus, and acellular pertussis...
Rurangwa J & Rujeni N
Pneumonia is a public health problem in the tropics, and the 7-valent pneumococcal conjugative vaccine (PCV-7) has been introduced in an effort to prevent the disease and therefore reduce childhood...
Victor Suarez et al.
Abstract Streptococcus pneumoniae is the leading cause of bacterial pneumonia, meningitis and sepsis in children worldwide. Despite available evidence on pneumococcal conjugate vaccine (PCV) impact...
PrayGod G et al.
BACKGROUND: Mortality due to severe pneumonia during childhood in resource-constrained settings is high, but data to provide basis for interventions to improve survival are limited. The objective of...
Kjell Arne Johansson et al.
Background: Pneumonia and pneumococcal disease cause a large disease burden in resource-constrained settings. We pursue an extended cost-effectiveness analysis (ECEA) of two fully publicly financed...
Marta Moreira et al.
Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in...
Griffiths UK et al.
BACKGROUND: Introduction of new vaccines in low- and lower middle-income countries has accelerated since Gavi, the Vaccine Alliance was established in 2000. This study sought to (i) estimate the...
Syed Aljunid et al.
Pneumococcal disease is the leading cause of vaccine-preventable death in children younger than 5 years of age worldwide. The World Health Organization recommends pneumococcal conjugate vaccine as a...
Adebayo K. Akinsola, Martin O C Ota, Godwin C Enwere, Brown J Okoko, Syed M A Zaman, Mark Saaka, Ekpedeme D Nsekpong, Aderonke A Odutola, Brian M Greenwood, Felicity T Cutts, Richard A Adegbola
A 9-valent pneumococcal conjugate vaccine (PCV-9), given in a 3-dose schedule, protected Gambian children against pneumococcal disease and reduced nasopharyngeal carriage of pneumococci of vaccine...
Antti Tanskanen, Leilani T. Nillos, Antti Lehtinen, Hanna Nohynek, Diozele Hazel M. Sanvictores, Eric A.F. Simões, Veronica L. Tallo, Marilla G. Lucero
The goal of this Geographic Information System (GIS) study was to obtain accurate information on the locations of study subjects, road network and services for research purposes so that the clinical...
Celina M Hanson et al.
Vaccines are extremely powerful disease prevention agents and have the potential to save millions of lives. Tremendous scientific progress has been made in the past decade with several new vaccines...
Deron C. Burton et al.
There is a theoretical risk of adverse events following immunization with a preservative-free, 2-dose vial formulation of 10-valent-pneumococcal conjugate vaccine (PCV10). We set out to measure this...
Martí SG et al.
BACKGROUND: A recently developed 10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) is expected to afford protection against more than two thirds of isolates...
Francisco Noya et al.
To describe the immunogenicity and safety of a two-dose series of a quadrivalent meningococcal (serogroups A, C, Y and W) polysaccharide diphtheria toxoid conjugate vaccine (MenACYW-D) administered...
Aaron M. Harris, George Aol, Dominic Ouma, Godfrey Bigogo, Joel M. Montgomery, Cynthia G. Whitney, Robert F. Breiman, Lindsay Kim
With the accelerated introduction of new vaccines in low-income settings, understanding immunization program performance is critical. We sought to improve immunization history acquisition from...
Marie R. Griffin, Edward F. Mitchel, Yuwei Zhu, Carlos G. Grijalva, Andrew D. Wiese
ntroduction of the 7-valent pneumococcal conjugate vaccine (PCV7) into the childhood immunization schedule was associated with substantial reductions in invasive pneumococcal disease (IPD) and...
David Berlan
Advocacy, policy, research and intervention efforts against childhood pneumonia have lagged behind other health issues, including malaria, measles and tuberculosis. Accelerating progress on the issue...
Tae Un Yang et al.
Although pneumococcal vaccines had been recommended for the elderly population in South Korea for a considerable period of time, the coverage has been well below the optimal level. To increase the...
Werner Valdés et al.
In Honduras, until 2008, vaccine and injection supplies were financed with domestic resources. With the introduction of rotavirus vaccine in 2009 and pneumococcal conjugate in 2011, the country\'s...
Raphael Weinberger et al.
The objective of the study was to assess the vaccine effectiveness (VE) of PCV13 for invasive pneumococcal disease (IPD) regarding the extra six serotypes with a 3 + 1 schedule in Germany.
Gavi, the Vaccine Alliance
This evaluation assesses the extent to which the Advanced Market Commitment (AMC) pilot has achieved its stated objectives and the overarching goal to “reduce morbidity and mortality from...
Grant A Mackenzie et al.
The Gambian PCV programme reduced the incidence of invasive pneumococcal disease in children aged 2–59 months by around 55%. Further surveillance is needed to ascertain the maximum effect of the...
Centers for Disease Control and Prevention (CDC)
Pneumococcal conjugate vaccines (PCVs) are safe and effective for reducing illness and deaths caused by Streptococcus pneumoniae (1). Recommendations for PCV use from the World Health Organization...
Judith Spijkerman et al.
The use of 4 different PCV13 immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels after the booster dose for almost all serotypes....
Sven Arne Silfverdal et al.
As 13-valent pneumococcal conjugate vaccine (PCV13) is introduced, children who began vaccination with 7-valent pneumococcal conjugate vaccine (PCV7) may complete their vaccination with PCV13. This...
Sara Boccalin, Angela Bechini, Paolo Landa, Alessio Signori, Nicola Luigi Bragazzi, Lucia Arata, Daniela Amicizia , Giancarlo Icardi, Paolo Bonanni, Roberto Gasparini, Alexander Domnich, Donatella Panatto
Given the growing use and great potential of mobile apps, this project aimed to develop and implement a user-friendly app to increase laypeople\'s knowledge and awareness of invasive pneumococcal...
Catherine Weil-Olivier et al.
The burden of invasive pneumococcal disease in young children decreased dramatically following introduction of the 7-valent pneumococcal conjugate vaccine (PCV7). The epidemiology of S. pneumoniae...
Kate M. Edwards et al.
Acute exercise at the time of vaccination can enhance subsequent immune responses. However, the potential benefit of this effect will be its efficacy in boosting poor responses, and thus protection...
Cardoso CW et al.
To combat rising incidence of serogroup C meningococcal disease in the city of Salvador, Brazil, the Bahia state immunization program initiated routine childhood immunization with meningococcal C...
Lee M Hampton et al.
In this study, the researchers used data from the Active Bacterial Core surveillance system in the United States to determine whether a sentinel surveillance system involving either individual...
Anna Roca, John Townend, Philip C. Hill, Uzo Egere, Martin Antonio, Abdoulie Bojang, Abiodun Akisanya, Teresa Litchfield, David E. Nsekpong, Claire Oluwalana, Stephen R. C. Howie, Brian Greenwood, Richard A. Adegbola
The study findings show that vaccination of young Gambian children reduced carriage of VT pneumococci in vaccinated children but also in vaccinated and non-vaccinated older children and adults,...
Gili Regev-Yochay et al.
Pneumococcal infections cause major morbidity and mortality in developing countries. The researchers report the epidemiology of S. pneumoniae carriage in a developing region, the Gaza strip, and...
Sabrina Sgambatti et al.
In Brazil, 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in 2010 in the childhood routine immunization program. The researchers used primary data to evaluate the effect of PCV10 on...
Ercan TE et al.
The aim of our study was to evaluate the effect of the seven-valent pneumococcal conjugate vaccine which has recently been included in the national immunization schedule on the nasopharyngeal...
Katherine L. O’Brien
Pneumococcal conjugate vaccine (PCV) was first licensed in 2000 as a 7-valent product and is now available as 10- and 13-valent products (PCV10 and PCV13). As recommended by the World Health...
Pui-Ying Iroh Tam et al.
The study seeks to examine whether there is a different clinical profile and severity of invasive pneumococcal disease (IPD) in children caused by nonvaccine types in the era of 13-valent...
Zitta Barrella Harboe et al.
The impact of the 13-valent pneumococcal conjugate vaccine (PCV13) at the population level is unclear. We explored PCV13\'s effect in reducing invasive pneumococcal disease (IPD)–related morbidity...
Hannah Christensen et al.
The study concludes that in the short term, case reduction is greatest with routine infant immunisation (26.3% of cases averted in the first five years). This strategy could be cost effective at £3...
García Gabarrot G et al.
In 2008, a 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the routine childhood immunization program in Uruguay, with a 2+1 schedule. In 2010, PCV13 replaced PCV7, and the same...
Bruce Y. Lee et al.
Although the substantial burdens of rotavirus and pneumococcal disease have motivated many countries to consider introducing the rotavirus vaccine (RV) and heptavalent pneumococcal conjugate vaccine...
D. Lévy-Bruhl, A. Lepoutre, L. Gutmann, C. Janoir, F. Dorléans, S. Georges, E. Varon
Vaccination with the 7-valent pneumococcal conjugate vaccine (PCV7) was recommended in France in 2003 for children <2 years. The 13-valent conjugate vaccine (PCV13) replaced PCV7 in 2010. The...
Chelsea A. Caya et al.
Currently, one lifetime booster of a 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for those at highest risk of invasive pneumococcal disease (IPD) 3–5 years after initial...
Pauline A Waight et al.
The 13-valent pneumococcal conjugate vaccine (PCV13) protects against key serotypes that increased after routine immunisation with the seven-valent vaccine (PCV7), but its potential for herd...
Emmanuelle Varon et al.
Highlights •Before and after PCV13 implementation, the ST relationship between carriage and IPD was investigated. •In children <2 years old, 569 IPD and 355 Sp isolated from 1212 healthy were...
Eugene D. Shapiro
The first vaccines to prevent pneumococcal infections, crude preparations of killed bacteria, were developed by Sir Almroth Wright in 1911 to try to alleviate the high mortality and morbidity among...
Gladstone RA et al.
Streptococcus pneumoniae is an important pathogen worldwide. Accurate sampling of S. pneumoniae carriage is central to surveillance studies before and following conjugate vaccination programmes to...
Najla A. Lakkis, Dina M. Mahmassani, Ghassan N. Hamadeh, Alexandra S. Ghadieh
BACKGROUND: Invasive pneumococcal disease is one of the most important vaccine-preventable diseases threatening the adult community due to missed opportunities for vaccination. This study compares...
Mueller JE et al.
The study conludes that serotype 1 causes the majority of cases with a relatively constant age-specific incidence. Pneumococcal carriage is common in all age groups including adults. Vaccination...
Roxanne E Strachan et al.
Although the PCV7 has substantially reduced the rates of invasive pneumococcal disease, reports from around the world suggest that the incidence of empyema in children has increased following the...
Jean-Marc Collard et al.
The epidemiology of pneumococcal meningitis in the African ‘meningitis belt’ is poorly studied. In order to ensure an effective vaccination strategy and post-vaccination surveillance, the...
Gavi, the Vaccine Alliance
Early one cloudless morning, Oscar Kai was perched on a Yamaha motorcycle clutching his laptop to his chest as he bumped along a dirt road past groves of coconut palms and fields of corn. He was...
S Torres-Rueda, HED Burchett, UK Griffiths, P Ongolo-Zogo, J Edengue, Y Kitaw, M Molla, L Gelmon, W Onyango-Ouma, M Konate, S Mounier-Jack
Abstract Background: Pneumonia is a main cause of under-five mortality in low-income settings. The pneumococcal conjugate vaccine (PCV) has been introduced in many countries as a tool in the...
Lode Schuerman, Dorota Borys, Ana Strezova, Juan Pablo Yarzabal, Nancy François, Fakrudeen Shafi, Ogobara Doumbo, Aminata Diallo, Amagana Dolo, Gaoussou Santara, Almahamoudou Mahamar, Youssoufa Sidibe, Amadou Barry, Yahia Dicko, Alassane Dicko
Pneumonia is still the leading cause of death among African children with pneumococcal serotypes 1 and 5 being dominant in the below 5 y of age group. The present study assessed the safety,...
S. Naito et al.
Heptavalent pneumococcal conjugate vaccine (PCV7) was introduced to Japan in 2010. The researchers investigated the impact of PCV7 on childhood community-acquired pneumonia (CAP) and pneumococcal...
Frederic Wallet, A. G. Chapoutot, Alain Martinot, Emmanuelle Varon, François Dubos, Marion Lagrée, Olivier Guilluy, Rodrigue Dessein
The impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on the incidence of pneumococcal meningitis (PM) in children is unknown. To determine this impact, a descriptive multicentre...
Andrea C. Farnham, Christopher M. Zimmerman, Vikki Papadouka, Kevin J. Konty, Jane R. Zucker, Geetha V. Nattanmai, Sherly Jose, Jennifer B. Rosen
Invasive pneumococcal disease (IPD) is a leading cause of pneumonia, meningitis, and bacteremia in children. In March 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) was introduced to the...
World Health Organization (WHO)
This document gives technical guidance into monitoring and using immunization data. More specifically, it covers data collection and reporting mechanisms, as well as how to use the data for...